Friday, July 25, 2014 Last update: 6:33 AM - All Company Technology News Since 1996

Fibrocell Science to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on March 17

Companies mentioned in this article: Fibrocell Science, Inc.

EXTON, Pa. -- (BUSINESS WIRE) -- Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that it will report fourth quarter and full-year 2013 financial results and provide an update on the morning of March 17, 2014. The update will include its collaboration with Intrexon Corporation (NYSE:XON). David Pernock, chairman and chief executive officer of Fibrocell, will host the conference call and webcast at 8:30 a.m. EDT, Mar. 17, 2014.

The conference call may be accessed by dialing 855-629-3857 for domestic callers and 678-509-8772 for international callers. Please specify to the operator that you would like to join the "Fibrocell Science Fourth Quarter and Full Year 2013 Financial Results Call, conference ID#: 10568066." The conference call will be webcast live under the investor relations section of Fibrocell's website at, and will be archived there for 90 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The company’s collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products. Fibrocell’s collaboration with UCLA—focusing on skin-derived stem cells and more efficient ways to convert skin cells to other cell types—holds potential for future discovery and development of autologous cellular therapeutics. For additional information, visit

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. Forward-looking statements include, without limitation, the ability of Fibrocell to present proof of concept data this year for its RDEB study and to develop breakthrough therapies for the treatment of skin and connective tissues diseases. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results.

Copyright © Business Wire 2014

Fibrocell Science, Inc.
Gregory Weaver, +1 484-713-6000
Chief Financial Officer
Investor Relations:
S.A. Noonan Communications, LLC
Susan Noonan, 212-966-3650